Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
This trial is active, not recruiting.
|Start date||May 2008|
|End date||November 2008|
|Trial size||21 participants|
|Trial identifier||NCT00704782, DIM13|
The purpose of this study is to assess the safety and efficacy of Dimebon in combination with donepezil (Aricept) in the treatment of Alzheimer's disease.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Phoenix, AZ||Banner Alzheimer's Institute||no longer recruiting|
|Phoenix, AZ||Barrow Neurological Institute||no longer recruiting|
|Phoenix, AZ||Xenoscience, Inc.||no longer recruiting|
|Sun City, AZ||Sun Health Research Institute||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
To assess the safety of Dimebon in combination with donepezil (Aricept)
time frame: week 12
Male or female participants at least 50 years old.
Inclusion Criteria: - Alzheimer's disease - On donepezil (Aricept) - Caregiver who cares for the patient at least 5 days per week Exclusion Criteria: - Unstable medical illnesses or significant hepatic or renal disease - Other primary psychiatric or neurological disorders
|Official title||An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease|
Call for more information